Company Analysis
Sign in

Cabaletta Bio, Inc. (CABA)

Nasdaq: CABA · Biological Products, (No Diagnostic Substances) · Philadelphia, PA · filing with the SEC since 2018
Full chart Alerts Compare
Grade5.6
◀ Past 5.9● Present 5.5▶ Future 5.6
6 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
Revenuen/a
Net income-$168M-44.9%
Earnings per share$-2.10+10.3%
Operating cash flow-$131M-48.6%
Cash$83.0M-49.4%
Debtn/a
Shareholders’ equity$112M-26.4%
Shares, dilutedn/a
Return on equity-149.8%
The recordfrom its filings
Filings in 202663
Newest filingNov 12 · SCHEDULE 13G/A
Annual reportMar 23, 2026
Quarterly reportNov 5, 2026
Next report due10-K by Mar 31
Insider sales, 12 months$0.00
Insider buys, 12 months$300,000
Patents grantedn/a
Filer categoryNon-accelerated filer<br>Smaller reporting company
Trailing twelve months to Sep 2026Net income -$190MCash from operations -$162Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
1819202122232425
As filed, in USD. Nothing here is a forecast.

News

Nov 9, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
Nov 5, 2026 · SEC EDGAR · Form 10-Q
Quarterly report
Open the filing on sec.gov
Nov 5, 2026 · SEC EDGAR · Form 8-K
Results released
Open the filing on sec.gov
Sep 14, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton CABA · research, not advice